In R&D Shakeup, Pfizer Tries New Outsourcing Model
This article was originally published in The Pink Sheet Daily
Contract research organizations Icon and Parexel will become Pfizer's primary clinical trail service providers under the new partnerships.
You may also be interested in...
While the industry does need more staff, it is reluctant to take the risk of hiring permanent full-time employees.
As Big Pharma continues its restructuring initiatives to outsource services to lower-cost emerging markets, Chinese and U.S. contract research organizations with the largest footprints and broadest capabilities will benefit from the ongoing trend, according to two recently released surveys on the CRO industry
As Big Pharma companies increasingly look to emerging markets to capture some of the growth lost from the patent cliff in the U.S. and Europe, they are also shifting focus more to branded generics, leaving some investors to question whether companies would be better off spinning out their emerging market units, which would leave behind smaller companies focused on the core business of developing and marketing innovative therapies